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INTRODUCTION
Between October 1, 1997, and September 30, 1998, the
Infectious Diseases Working Party of the European Group
for Blood and Marrow Transplantation (EBMT) conducted
a prospective study of community-acquired respiratory virus
(CRV) infections in all patients undergoing allogeneic or
autologous stem cell transplantation (SCT) in the EBMT’s
37 member institutions. The goal of the study was to deter-
mine the frequency of, risk factors for, and outcome of CRV
infections in SCT recipients [1].
STUDY DESIGN 
This study was a 1-year prospective study. All patients
who underwent allogeneic or autologous SCT at EBMT
institutions during the study period were enrolled. Each
center used its own methods for diagnosing CRV infections,
but all agreed to complete the same case report form. 
Because a small number of respiratory infections
occurred during the year of the original study (phase I), a
second phase of the study was undertaken (phase II). During
phase II, additional cases were collected prospectively for
18 months, beginning in October 1998, using the same pro-
cedures employed in phase I.
PHASE I RESULTS
Incidence of CRV Infection
During phase I, 819 patients underwent allogeneic
SCT and 1154 patients underwent autologous SCT at the
37 EBMT centers. CRV infections developed in only 40 of
these 1863 patients: 35 allogeneic and 5 autologous SCT
recipients.
Pediatric transplantation centers reported the highest
frequencies of CRV infection for both patient populations.
Although the incidence of infection may actually have been
higher at these centers than at other centers, the greater
ease of diagnosis in pediatric patients, who have higher viral
loads [2], as well as the centers’ greater experience in look-
ing for these infections might have contributed to the
higher reported frequencies at these centers. 
Of the 40 CRV infections diagnosed during phase I,
2 were present before the start of the conditioning period,
9 were diagnosed between 5 days prior to SCT and day 28
after SCT, and 29 occurred after engraftment (at day 29 or
later). Of the 9 patients whose CRV infections were diag-
nosed before day 28, 7 underwent allogeneic SCT and
2 underwent autologous SCT. For those whose infections
were diagnosed at day 29 or later, 26 of 29 were in the allo-
geneic SCT group.
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Of the 40 CRV infections, 20 were attributed to respira-
tory syncytial virus (RSV), 4 to parainfluenza viruses, and
16 to inﬂuenza A virus. Of the 20 RSV infections, 14 (70%)
were lower respiratory tract infections (LRTIs), whereas
only 7 (44%) of 16 infections attributed to inﬂuenza virus A
infections were LRTIs and only 1 (25%) of the 4 parain-
ﬂuenza virus infections was an LRTI. 
Survival Among Patients With CRV Infection
Overall, 78% of SCT recipients with CRV infections
survived (Table 1). No differences in survival were seen
among patients who acquired CRV infections prior to or
following engraftment or before or after day 28 following
SCT. Approximately 75% of patients survived CRV infec-
tion no matter when it occurred. 
Survival rates for patients with RSV infections (80%)
and those with inﬂuenza A virus infections (75%) were simi-
lar to the overall survival rate, whereas all patients with
parainﬂuenza virus infections survived (Table 1).
We also examined the proximate cause of death among
patients with a diagnosis of RSV or inﬂuenza A virus infection
at the time of death. This analysis was performed in an attempt
to arrive at a more precise deﬁnition of the outcome of CRV
infection in this population. When CRV infection mortality
was strictly defined as mortality due to respiratory failure
caused by a speciﬁc virus, mortality among patients with CRV
infection declined. Of the 20 patients with RSV infection,
5 died during the course of the study, but only 3 deaths were
attributable to the RSV infection; 1 patient died of graft-
versus-host disease and 1 patient died of aspergillosis. A similar
analysis was applied to patients with inﬂuenza A virus infec-
tions. Of 16 patients with inﬂuenza A virus infection, 4 died,
but only 2 died of inﬂuenza-related respiratory failure.
The respiratory virus–associated mortality rate among
the allogeneic SCT recipients was 1.1%, which, although
low, is still signiﬁcant. No patients who underwent autolo-
gous SCT died of respiratory infections.
PHASE II RESULTS
During phase II of the study, 53 additional cases of CRV
infection were identified, of which 31 were upper respira-
tory tract infections (URTIs) and 25 were LRTIs. As in
phase I, the majority of CRV infections were caused by RSV
(26 cases) or inﬂuenza A virus (23 cases), with parainﬂuenza
virus accounting for 3 cases and rhinovirus for 1 case. 
MORTALITY IN PHASE I AND PHASE II
The overall mortality rate for the combined phase I and
phase II cases of CRV infection was approximately 25%
(Table 2). The mortality rate for RSV infection was 30% over-
all but approached 35% in the allogeneic SCT population.
Respiratory infection–associated mortality was 15% overall
and approached 20% for RSV infections among allogeneic
SCT recipients. For inﬂuenza A virus infections, the overall
mortality rate was 23%, which is within the range reported in
other studies [3,4], and the respiratory infection–associated
mortality rate was 15%. Fatal inﬂuenza A virus respiratory
infection occurred in 2 autologous SCT recipients. 
RISK FACTORS FOR LRTI
Three factors were identified that placed patients at
increased risk of LRTI: lymphocytopenia, neutropenia, and
relationship to donor. However, multivariate analysis showed
Table 1. Survival of SCT Recipients with CRV Infections at 37 EBMT Centers, 1997 to 1998
All Patients, Survived/Infected Allogeneic SCT, Survived/Infected Autologous SCT, Survived/Infected
Overall 31/40 (78%) 26/35 (74%) 5/5 (100%)
Time of diagnosis
Before conditioning 2/2 2/2 NA
Days –5 to 28 7/9 5/7 2/2
≥Day 29 22/29 19/26 3/3
Virus
RSV 15/20 13/18 2/2
Influenza A 12/16 10/14 2/2
Parainfluenza 4/4 3/3 1/1
Table 2. Mortality Attributable to CRV Infection Among SCT Recipients with CRV Infections at EBMT Centers: Combined Results of Phases I and II
Infections, n Deaths, n (%) Deaths Due to Respiratory Virus, n (%)
Total 93 23 (25) 14 (15)
RSV (total) 46 14 (30) 8 (17)
Allogeneic SCT 42 14 (33) 8 (19)
Autologous SCT 4 0 0
Influenza A (total) 39 9 (23) 6 (15)
Allogeneic SCT 30 7 (23) 4 (13)
Autologous SCT 9 2 (22) 2 (22)
Parainfluenza virus 7 0 0
Rhinovirus 1 0 0
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that only lymphocytopenia was a signiﬁcant risk factor for
LRTI among all patients with CRV infections (P = .008;
odds ratio, 2.52; 95% conﬁdence interval [CI], 1.26-5.06).
Lymphocytopenia was also found to be a signiﬁcant risk fac-
tor for LRTI among those with RSV infection (P = .01; odds
ratio, 3.04; 95% CI, 1.26-7.35) but not among those with
inﬂuenza virus infection (P = .11; odds ratio, 2.84; 95% CI,
0.73-11.01), probably owing to the low number of patients.
TREATMENT OF RSV INFECTION IN SCT RECIPIENTS
The most widely used treatment for RSV infection in
immunocompromised patients is combination therapy with
ribavirin and intravenous immunoglobulin (IVIG) [5-7], but
ribavirin [8,9] may also be used alone.
Of the 33 patients with RSV URTI, 16 were untreated.
None of these untreated patients died, whereas 1 of the
6 patients treated with ribavirin and IVIG died, and 2 of the
12 patients treated with ribavirin alone died. The impact of
treatment on survival depends on the severity of the infec-
tion, which was not categorized among these patients. It is
possible that only patients with severe illness were treated. 
Treatment had a modest effect on all-cause mortality
rates among SCT recipients with RSV LRTI. Of 54 such
patients, 4 (40%) of the 10 patients who received no treat-
ment survived; 5 (45%) of the 11 patients who received rib-
avirin plus IVIG survived; and 14 (50%) of the 28 patients
treated with ribavirin alone survived. A controlled clinical
trial would be necessary to determine the true effect of any
treatment or of a particular treatment, given the 40% sur-
vival rate among untreated patients. 
When the analysis was repeated excluding patients with
RSV LRTI who died of another cause, intervention with
either ribavirin or ribavirin plus IVIG had a slightly greater
effect on survival than in the previous analysis. 
Although intravenous ribavirin is not widely used in the
United States, it has shown some promise, with or without
aerosolized ribavirin, in a small uncontrolled European
study of bone marrow transplantation recipients with
proven CRV infection [10]. We therefore compared the out-
comes for intravenous ribavirin versus inhaled ribavirin in
SCT recipients with RSV LRTI. In these patients, ribavirin
was similarly effective when administered by either route
and with or without IVIG. Again, because 40% of patients
in the untreated group survived, a controlled trial would be
required to determine the comparative efficacy of these
alternative treatments. 
We also analyzed the effect of treatment with ribavirin
on LRTI caused by parainfluenza virus. Six of 9 patients
who received both intravenous and inhaled ribavirin and
8 of 15 patients who received only inhaled ribavirin sur-
vived; both groups also received IVIG. 
CONCLUSIONS
In a prospective study enrolling 1863 patients undergoing
SCT at 37 EBMT centers, CRV infections were diagnosed in
approximately 2% of patients overall. The mortality rate
associated with respiratory virus infection was approximately
1.1% among recipients of allogeneic SCT; no recipients of
autologous SCT died of this cause. RSV and inﬂuenza A virus
were responsible for most CRV infections in the allogeneic
SCT group; RSV infections were responsible for higher res-
piratory virus–associated mortality rates than were inﬂuenza
A virus infections. An 18-month extension of the prospective
study that enrolled an additional 53 patients conﬁrmed the
study’s essential ﬁndings and showed lymphocytopenia to be
an independent risk factor for development of LRTI.
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